• D-Wave’s research shows that quantum-based blockchain operations could use up to 1,000 times less electricity than classical computing methods.
• In an industry first, D-Wave successfully deployed blockchain operations across four of its cloud-based quantum computers in North America.
• The company’s proof of quantum work algorithm leverages quantum-generated hashes, providing an added security layer.
• The novel quantum blockchain architecture follows the company’s recent quantum supremacy demonstration, serving as another example of how D-Wave helps customers realize the value of quantum computing now.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has published a research paper introducing a new quantum blockchain architecture that could improve security and significantly reduce the electricity required for blockchain operations (https://ibn.fm/Tndwv). The paper, “Blockchain with Proof of Quantum Work,” details how quantum computing can be used to generate and validate blockchain transactions more efficiently than classical computers (https://ibn.fm/6nVTE).

The company has also conducted the first-ever demonstration of distributed quantum computing for blockchain. This involved deploying the new blockchain architecture across four of its cloud-based quantum computers located in Canada and the United States. According to D-Wave, the results show that quantum computing can support stable blockchain operations across different generations of hardware. “This is the first time a blockchain has successfully operated on a distributed network of four quantum computers across two countries,” said Dr. Mohammad Amin, chief scientist at D-Wave.

Traditional blockchains rely on hashing functions and proof of work (“PoW”) algorithms to validate transactions. These operations are computationally demanding and consume significant amounts of electricity. For example, Bitcoin mining alone is estimated to use as much electricity annually as Poland consumes.

D-Wave’s paper highlights how the company built and tested a “proof of quantum work” algorithm that uses quantum computation to generate and validate blockchain hashes. The research shows that replacing classical computation with quantum-based hashing and proof of work could lead to significant energy savings. The paper states that, in this context, the proof of quantum work algorithm could reduce electricity consumption by up to a factor of 1,000.

Furthermore, this algorithm could enhance security by generating blockchain hashes using quantum computation, instead of classical computers. By integrating quantum-generated hashes, the system can eliminate some of the vulnerabilities associated with traditional proof-of-work models.

D-Wave’s approach relies on programmable spin glasses, which were used in its recent quantum supremacy demonstration. These quantum-generated hashes provide a more complex security framework than classical methods, potentially making blockchain networks more resistant to attacks.

“Despite spanning two generations of D-Wave annealing quantum computers with different architectures and fabrication stacks, the systems’ outputs were able to cross-validate each other and facilitate stable blockchain operation for thousands of transaction blocks. We believe that this approach could significantly reduce energy consumption and enhance security,” Dr. Amin added.

Blockchain technology has applications beyond cryptocurrency, including supply chain management, healthcare, identity verification, and decentralized finance. The introduction of quantum-powered blockchain could address some of the scalability and energy consumption challenges currently faced by blockchain networks.

D-Wave is inviting businesses and researchers to explore potential use cases for this technology. The D-Wave(TM) annealing quantum computers used in the company’s recent quantum supremacy demonstration and this new blockchain research are available for customers to use today via D-Wave’s Leap(TM) real-time quantum cloud service.

“Coming off the heels of our recent quantum supremacy demonstration, this serves as yet another example of how D-Wave is helping customers realize the value of quantum computing now,” said Dr. Alan Baratz, CEO of D-Wave. “We invite the blockchain community to work with us to utilize this exciting new use case for quantum computing.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage(TM) quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2(TM) systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

• The company’s AI-driven software helps clinics transition to value-based care and optimize revenue streams, offering providers superior visibility into insurance contracts and associated reimbursements.
• Adageis provides advocacy for healthcare organizations, identifying discrepancies in payments and ensuring they are fairly compensated for services.
• The platform allows providers to assess which insurance contracts align best with their financial goals and patient care priorities, improving financial planning.

Healthcare providers often struggle to navigate complex insurance contracts to determine whether they are receiving proper reimbursement for services. A lack of transparency in how the process unfolds can result in lost revenue and financial instability, particularly for smaller clinics and new practices.

Adageis, a forward-thinking healthcare technology company, is reshaping patient care through flexible AI-centric software solutions for healthcare organizations. The company offers a software solution designed to help providers understand what they should be paid under each insurance contract, with insights into revenue expectations.

Adageis’ AI-driven platform allows clinics to quickly and easily:

• Compare expected vs. actual payments from insurance companies
• Identify underpayments and reimbursement gaps
• Analyze financial performance under different contracts

By providing real-time visibility into these details, healthcare organizations can make more informed decisions about contract negotiations and patient care models.

As healthcare moves away from fee-for-service models toward value-based care, many providers struggle to adjust. Adageis offers tools to help new practices transition smoothly to value-based care structures, highlighting the most profitable insurance contracts while maintaining high-quality care, and ensuring that providers are fairly compensated for delivering effective patient outcomes.

Beyond financial insights, Adageis positions itself as an advocate for healthcare providers. The company’s technology enables organizations to negotiate better contracts with insurers, providing clarity on expected revenue before signing agreements, and making sure they are paid what they are owed for patient care. By empowering providers with solid data, Adageis aims to level the playing field between healthcare organizations and insurers.

The healthcare technology sector is experiencing growing investor interest, particularly in solutions that address billing inefficiencies and revenue optimization. Adageis offers practical AI applications in healthcare finance, designed to provide increased transparency, simplicity, and real financial gains. The company stands out as a promising investment opportunity in a rapidly evolving landscape.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• MAMO recently participated in several vendor events to strengthen strategic retail partnerships
• Company recognizes “our success is intrinsically tied to our retail partners and the communities they serve,” states CEO
• By engaging directly with retail partners, Massimo Group gains invaluable insights into customer preferences and emerging trends

In today’s competitive business environment, robust retail partnerships are essential for companies aiming to expand their market reach and enhance brand visibility. Such collaborations enable businesses to leverage the strengths of their partners, ensuring products and services are accessible to a broader customer base. Massimo Group (NASDAQ: MAMO), a manufacturer of powersports vehicles, exemplifies this strategy by actively engaging in key industry events to fortify its retail alliances.

According to the company, Massimo Motor recently participated in the Rural King Vendor Summit, the Tractor Supply Company & PetSense Annual Supplier Meeting (“ASM”), and the Partner Trade Show (ibn.fm/Sm8eG). These events serve as platforms for suppliers and retailers to collaborate, discuss market trends and align strategies to meet consumer demands effectively. Massimo’s involvement underscores its commitment to strengthening relationships with major retail partners, ensuring its products are accessible to a broad consumer base.

“At Massimo Motor, we recognize that our success is intrinsically tied to our retail partners and the communities they serve,” said David Shan, CEO of Massimo Motor. “The customers who shop at Rural King and Tractor Supply demand quality, reliability and affordability, and we are committed to delivering products that exceed those expectations.”

Massimo’s participation in these vendor summits is not only about showcasing its lineup of UTVs, ATVs and other outdoor vehicles, but also about listening and learning. By engaging directly with retail partners, the company gains invaluable insights into customer preferences, emerging market trends and opportunities for improvement. This knowledge enables Massimo to refine its product offerings and ensure its vehicles deliver the durability and performance that rural customers rely on for work and recreation.

The shared customer base between Massimo, Rural King and Tractor Supply “represents a segment of consumers who prioritize practicality, value and high-quality equipment,” the company stated. “By maintaining a close partnership with these retailers, Massimo reinforces its commitment to providing vehicles that meet the real-world needs of farmers, ranchers and outdoor enthusiasts across the country.”

The company also noted that its participation in these types of events represents its proactive approach to market expansion and strategic growth. “Strengthening partnerships with established retail leaders ensures that Massimo products remain competitive, accessible, and positioned for long-term success,” the company observed.

In addition to strengthening retail partnerships, Massimo has made strategic moves to enhance its operational efficiency. The company recently announced the transition of its MVR Golf Cart series production to its facility in Garland, Texas. This move aims to improve quality control and streamline production processes, further solidifying Massimo’s commitment to delivering top-notch products to its customers.

MAMO’s strategic emphasis on strengthening retail partnerships, coupled with its commitment to innovation and quality, positions the company well in the competitive powersports industry. By aligning closely with key retailers and focusing on delivering value-packed products through the launch of its new online sales platform, Massimo is poised to meet the evolving needs of consumers and maintain its growth trajectory in the market.

Founded in 2009, Massimo Motor has established itself as a key player in the powersports industry. The company operates a 376,000-square-foot facility in Garland, Texas, where it designs and manufactures a diverse range of vehicles. Massimo’s product lineup includes utility task vehicles (“UTVs”), all-terrain vehicles (“ATVs”), and other off-road and on-road vehicles, all known for their performance, durability, and affordability. This diverse portfolio caters to both recreational enthusiasts and professionals seeking reliable machinery for various tasks.

For more information, visit the company’s website at massimomotor.com, massimomarine.com, and massimoelectric.com

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

The MoneyShow Income, Growth, & Value Virtual Expo will be held from April 29-30, 2025, as a virtual event. The online conference features the financial industry’s brightest minds sharing their wisdom and advice. Attendees can connect with them during the LIVE presentations and get their queries solved.

The MoneyShow Virtual Expo will show investors how they can both safeguard and grow their portfolios. Attendees can directly chat with distinguished experts to learn pro tips on creating a strong and diverse portfolio. The MoneyShow organization brings in 44 years of industry experience offering traders and investors sound financial and trading advice, resources, and collaboration opportunities to enable them to build their wealth.

Whether you’re a seasoned investor or a newcomer, you won’t want to miss the event.

Top Reasons to Attend:

• Gain valuable insights from top financial experts.
• Learn about income-generating investments, growth opportunities, and value-based strategies.
• Network with like-minded investors and traders.
• Learn about key market trends and make informed investment decisions.

From growth-stage to veteran companies, several players will showcase their products, services, and investment opportunities. Experts will offer live market analysis and sound recommendations on many investment topics. Attendees can connect with industry experts, investors, and peers to explore new investment opportunities and expand their horizons.

Attendees will also have access to interactive, virtual booths that offer message boards, research data, educational videos, phenomenal discounts, and other valuable information. To top it all off, the event provides a digital briefcase for attendees to assemble, download, and store all the collected information in one place.

To learn more, please visit https://ibn.fm/ofEPM.

• Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026.
• SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light.
• The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate, HyBryte(TM) (“SGX301”), has already demonstrated positive results in a prior phase 3 trial, and Soligenix is now conducting a phase 3 replication study to further validate its efficacy and safety (https://ibn.fm/zdRnQ). This development marks an important milestone in the company’s mission to address an urgent medical need in a condition with limited treatment options.

“We are pleased to be initiating patient enrollment into our FLASH2 study,” said Soligenix president and CEO Christopher J. Schaber (https://ibn.fm/LjfXu). “FLASH2 is expected to enroll patients in the United States and Europe, with a formal interim analysis anticipated early in 2026. Given the extensive engagement with the CTCL community, the esteemed Medical Advisory Boards in the U.S. and Europe, key patient advocacy groups like the Cutaneous Lymphoma Foundation, as well as our previous trial experience with this disease, accelerated enrollment in support of this study is anticipated. We look forward to providing periodic updates on the trial’s progress in 2025.”

CTCL is a rare and chronic form of non-Hodgkin’s lymphoma that primarily affects the skin, leading to symptoms such as red, scaly patches, growths and severe itching (https://ibn.fm/JXiDN). Patients with early-stage CTCL often struggle to find effective treatments that are both safe and well-tolerated over long periods. Current treatment options include corticosteroids, phototherapy and chemotherapy. These treatments often come with limitations, such as toxicity, inconsistent responses and adverse side effects.

HyBryte(TM) is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. This revolutionary treatment offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision.

The initial phase 3 trial (“FLASH”) of HyBryte(TM) showed strong efficacy, demonstrating a statistically significant response in patients compared to placebo. The study results indicated that HyBryte(TM) was not only effective in reducing lesion size and severity but also presented a favorable safety profile, making it a compelling option for long-term disease management. The positive data from this initial trial has led Soligenix to move forward with the FLASH2 replication study, which aims to confirm the results in a larger patient population and further establish HyBryte(TM) as a viable front-line treatment for early-stage CTCL.

The ongoing phase 3 replication study is designed to potentially meet the stringent requirements of regulatory agencies, in order to strengthen the case for HyBryte(TM) as a commercially available treatment. If successful, this study could pave the way for regulatory approval worldwide, bringing a much-needed new option to patients who have long been underserved by existing therapies. The ability of HyBryte(TM) to deliver effective results with minimal systemic exposure makes it particularly well-suited for chronic conditions such as CTCL, where long-term management is essential.

Soligenix is positioning itself as a leader in the rare disease space by focusing on therapies that address critical gaps in treatment. In addition to HyBryte(TM), the company has a diversified pipeline that includes other promising candidates targeting conditions such as oral mucositis, and Behcet’s Disease, as well as mild-to-moderate psoriasis. By leveraging its proprietary drug development expertise and commitment to scientific rigor, Soligenix is working to bring life-changing treatments to patients who have few, if any, safe and effective therapeutic alternatives.

The significance of Soligenix’s phase 3 replication study extends beyond just the CTCL community. Success in this trial could reinforce the company’s broader strategy of using innovative therapeutic approaches to tackle rare and difficult-to-treat diseases. The progress of HyBryte(TM) also highlights the importance of photodynamic therapy as a novel and effective modality that could potentially be applied to other dermatological and oncological conditions.

As Soligenix moves forward with its pivotal phase 3 replication study, industry observers, investors, and medical professionals will be closely monitoring the results. A positive outcome could not only validate HyBryte(TM) as a groundbreaking treatment for early-stage CTCL but also elevate Soligenix’s standing as a leader in the rare-disease treatment space. The company remains dedicated to advancing its research and bringing new hope to patients facing life-altering conditions with limited treatment options.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Solving the ongoing hospitality labor crisis can create billion-dollar companies
• Nightfood’s unique RaaS business model lowers barriers to entry while maximizing revenue per client
• Nightfood’s subsidiaries Skytech and Future Hospitality Ventures (RoboOp365) provide breakthrough RaaS solutions for both front and back of house

The hospitality industry is undergoing a radical transformation as automation promises to forever change the hotel labor landscape. With the rapid evolution of AI, robotics has undergone a seismic change. No longer an expensive novelty that delivered little value to hotel operators, robotics is becoming a must-have to remain in business and compete.

Combining the most advanced AI-driven robotics technology with its unique Robots-as-a-Service (“RaaS”) financial model, Nightfood Holdings (OTCQB: NGTF) is poised to lead the hospitality industry into the robotics age.

From mobile check-ins and digital room keys to online concierge services and smart room features, technology enables hotels to provide seamless experiences for both guests and staff. This not only boosts customer satisfaction but also improves operational efficiency by automating repetitive tasks and optimizing resource management. As we’ve seen in the past, falling behind on tech can be fatal.

This means the entire industry will be racing to adopt AI-driven robotics in the next one to three years. This is not optional.

As a leader hospitality tech, NGTF’s unique RaaS business model is a key differentiator investors should consider when placing their sector bets. RaaS allows hotel operators to quickly and easily incorporate mission-critical robotics without massive upfront capital expenditures.

Instead of having to purchase robotics upfront and then coordinate all elements of integration and maintenance, hotel operators can lease their robotics tech through NGTF. By doing this, a hotel can seamlessly integrate robotics into their operations with a simple line-item expense on their income statement. NGTF subsidiaries provide setup, installation, integration, training, and maintenance.

The benefits to NGTF are equally as powerful. Because RaaS significantly lowers barriers to entry, adoption rates go up and customer acquisition costs go down. The leases increase client satisfaction and create a sticky and predictable revenue stream with exceptionally high retention rates and customer lifetime value.

As the tech evolves at breakneck pace, hotels can easily upgrade to the latest version without being stuck with out of date “last year’s model.”

NGTF subsidiaries Skytech and Future Hospitality Ventures can automate everything from cleaning linens and trash removal to food preparation and deliveries.

The service robotics market is projected to reach $107.75 billion by 2030 (ibn.fm/k7Skz). How much investor value will be created in coming years in this sector?

This presents an opportunity for forward-thinking investors who can see the critical role robotics will play in hospitality (ibn.fm/QdUHm).

Nightfood’s recent acquisition of Skytech Automated Solutions (ibn.fm/Cd3Le) is a major industry development. Skytech’s leadership team has decades of experience in hotel management, business operations, and technology-driven solutions.

Skytech is best known for its AI-driven Laundry Helper robot. Laundry Helper picks up and transports laundry and trash, reducing the burden on housekeeping staff. Equipped with advanced sensors, AI navigation, and robotic arms, it can operate elevators and open doors on its own, making it the perfect housekeeping assistant for hotels.

Already successfully deployed in its first properties from InterContinental Hotels Group and Hilton Worldwide Holdings, the Skytech team has its sights set on rapid industry expansion for Laundry Helper, as well as its Concierge, Matradee, and Sweeper robots.

Synergies can be expected between these offerings and the food prep and delivery bots provided by NGTF subsidiary Future Hospitality, allowing hotel operators to procure all their RaaS needs through Nightfood Holdings.

The industry is at a tipping point. In a few years, hotels without integrated robotics will seem as antiquated as jingly keys, smoking rooms, and in-room VCRs.

NGTF is leading the way.

For more information, visit the company’s website at NightfoodHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Quant Strats USA 2025, held on March 11 at Quorum by Convene in New York, brought together over 380 professionals in quantitative finance, with 70% of attendees representing the Buy-Side, including hedge funds, asset managers, and investment banks. The event reaffirmed its role as a premier forum for exploring advancements in artificial intelligence (“AI”), machine learning (“ML”), and large language models (“LLMs”) within finance, offering attendees unparalleled access to industry-leading insights and networking opportunities.

The conference featured over 50 expert speakers who examined how AI and ML are no longer just theoretical innovations but essential tools shaping investment strategies, risk management, and trade execution. AI & ML in Asset Management addressed how firms are integrating advanced algorithms into portfolio construction, risk assessment, and trade execution to drive efficiency and improve returns. The Future of Large Language Models (“LLMs”) in Quant Finance explored how LLMs are being leveraged for predictive modeling, sentiment analysis, and automating complex financial decision-making. The discussion underscored the increasing reliance on AI-driven insights to navigate evolving market conditions and improve performance.

A central theme throughout the event was the growing synergy between quantitative and fundamental investment strategies. Blending Quant & Fundamental Strategies featured leading portfolio managers and quant strategists who discussed the complexities of combining data-driven models with traditional financial analysis, highlighting the benefits and challenges of hybrid approaches. Meanwhile, Alternative Data & Alpha Generation explored how non-traditional data sources, ranging from satellite imagery to consumer transaction data, are unlocking new opportunities for alpha generation, providing firms with an edge in systematic trading.

With the rapid evolution of electronic trading, High-Frequency Trading & Execution Algorithms took a deep dive into the latest advancements in trade execution, latency reduction, and market-making strategies. The session provided a comprehensive look at how firms are optimizing execution in an increasingly automated environment. Meanwhile, Risk Management in a Volatile Market tackled the challenges of adapting quant strategies to turbulent market conditions, emphasizing the importance of robust risk frameworks in mitigating potential losses and ensuring long-term portfolio stability.

Beyond the content-rich sessions, Quant Strats USA 2025 offered extensive networking opportunities, allowing attendees to connect with top-tier data scientists, quantitative analysts, institutional investors, and technology providers. The event’s focus on practitioner-led discussions ensured that participants left with actionable takeaways, equipping them with cutting-edge tools and strategies to navigate the evolving landscape of quantitative finance.

The discussions and insights from Quant Strats USA 2025 will continue later this year at Quant Strats Europe, offering another opportunity for professionals to engage with global leaders in the field. As AI and ML continue to drive transformation in quantitative finance, staying ahead of these developments is crucial. Attendees of Quant Strats Europe can expect in-depth discussions on the latest trends, hands-on workshops, and expanded networking opportunities designed to help firms remain competitive in an increasingly data-driven industry. For more details and to secure participation, visit Quant Strats Europe.

• The company will present at the Jones Las Vegas Technology and Innovation Conference on April 8-9, to update investors on its lead drug candidate.
• The conference will provide one-on-one meetings and networking opportunities for institutional investors and executives.
• Clene recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS treatment.
• New analyses suggest CNM-Au8 improves survival for ALS patients, with a 4.1-month increase in restricted mean survival time.
• Clene plans to begin enrollment for a Phase 3 confirmatory trial (RESTORE-ALS) in mid-2025.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will participate in the upcoming Jones Las Vegas Technology and Innovation Conference at The Venetian Resort. The April 8-9 event, organized by JonesTrading and supported by B2i Digital, provides a platform for direct engagement between innovative companies and institutional investors (https://ibn.fm/fIKDc).

“We look forward to participating in the Jones Conference, which provides an opportunity to share our progress and connect directly with investors in a setting that fosters productive conversations,” said Rob Etherington, CEO and President of Clene.

The conference will feature keynote addresses from Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization, along with a Jones-hosted Golf Event and Cocktail Reception.

Commenting on the event, Alan Hill, CEO of JonesTrading, underlined that his firm and the conference are focused on creating a forum where public companies can communicate directly with the investment community, while B2i Digital, Inc. CEO David Shapiro underlined his company’s commitment to ensuring that companies participating in the Jones Conference have a platform to reach investors who are actively seeking new ideas and opportunities.

Clene’s presence at the Jones Conference offers investors a chance to engage with the company at a pivotal moment in its regulatory journey. At the event, the company will provide key updates about its lead drug candidate CNM-Au8 and its path to regulatory approval. CNM-Au8 is an oral suspension of gold nanocrystals designed to improve cellular energy production and utilization, which is critical for maintaining neuronal health. In several clinical trials, the drug candidate has been shown to improve survival rates in ALS patients, a finding supported by preclinical evidence that the drug works by improving central nervous system cells’ survival and function. The company recently received FDA guidance on using biomarker data to support an accelerated approval pathway for the drug.

Following a November 2024 meeting with the FDA’s Division of Neurology 1 (“DN1”), Clene was advised to analyze additional data from ongoing Expanded Access Programs (“EAPs”) to evaluate CNM-Au8’s impact on neurofilament light chain (“NfL”), a potential surrogate endpoint for ALS treatment. No significant safety concerns have emerged in over 800 patient years of CNM-Au8 use, and no serious adverse events (“SAEs”) have been linked to the treatment.

Clene expects to finalize a statistical analysis plan with the FDA in Q2 2025 before collecting and analyzing NfL biomarker data in Q3 2025, supporting a potential NDA submission in the second half of 2025.

New survival analyses compared CNM-Au8 (30 mg, Regimen C) against a concurrent control group (Regimen A) in the HEALEY ALS Platform Trial. Findings include:

• A 4.1-month improvement in restricted mean survival time (“RMST”) (p=0.045).
• Enhanced survival in severe ALS cases, with median survival extended by 11.9 months.
• A 44% decrease in mortality risk for patients with high baseline NfL levels (p=0.006).

To further evaluate CNM-Au8’s efficacy, Clene will launch the Phase 3 RESTORE-ALS trial in mid-2025. The study will assess overall survival as a primary endpoint and delayed ALS clinical worsening events as a secondary endpoint.

“We expect further regulatory guidance in 2025 on the critical next steps required to advance our CNM-Au8 NDA submission for the treatment of ALS under the accelerated approval pathway,” said Etherington. The company also continues to evaluate CNM-Au8’s impact on vision and cognition in multiple sclerosis patients, he added. “As always, we are incredibly motivated by our mission to help people suffering from ALS and other neurodegenerative diseases prolong their lifespan and improve their quality of life.”

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

The ZJ Alternative Products Expo will be held from April 3-5, 2025, at the Mana Wynwood Convention Center in Miami. The expo showcases the latest trends and the finest products and services of the counterculture community, tapping a worldwide audience. With Miami emerging as the epicenter of flavors, cultures, and smoke shops, the event aims to blend the local flavor of Florida with the rest of America.

ZJ Events organizes networking events by compiling valuable data on alternative products and presenting to leading brands, manufacturers, and dealers. They provide the counterculture community with a robust platform for exciting learning and business experiences in a safe and conducive environment. For the first time, the expo will offer B2B experience at the Alternative Products Expo.

The Alternative Products Expo offers unique experiences where local and global traders can network, strike deals, and learn about new innovations. Veterans and newcomers showcase exciting trends and products on the exhibition floor. The eclectic vibe, top-tier smoke shops, culinary adventures, vibrant nightlife, and confluence of cultures offer attendees an unforgettable experience.

Investors and enthusiasts can discover new avenues of business and opportunities, with immense new talent from the counterculture spectrum making a foray at the expo. The Alternative Products Expo in Miami offers business opportunities for newbies as well as veterans of the local smoke-shop community to expand their reach to global frontiers. Businesses and traders can network and connect on the event floor, fostering long-term relationships.

The attendees list consists of consumers, businesses, and enthusiasts from the local and international counterculture community. They not only come to discover new industry trends and products; they also enjoy the buzz and vibe of the Alternative Products market.

To learn more, please visit https://ibn.fm/TbO4J.

• SolarBank announced the sale of a 3.26 MW Camillus Solar Project to Solar Advocate Development LLC.
• The project will be built on a closed landfill and provide renewable energy to local subscribers.
• The project was awarded $1.06M in state incentives awarded under the NY-Sun Program.
• This marks the eighth project SolarBank has developed for Solar Advocate since 2018, and is the latest in a series of recent solar projects and battery storage systems the company has been developing.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced the sale and related construction contract for the 3.26 MW Camillus Solar Project for Solar Advocate Development LLC in a deal valued at $7.3 million USD (https://ibn.fm/qFjN7).

The project, located on a closed landfill site in Camillus, Onondaga County, New York, will operate as a community solar installation, allowing local residents and businesses to subscribe and receive credits on their utility bills for using renewable energy.

SolarBank has begun engineering and initial construction of the project and is working under an engineering, procurement, and construction (“EPC”) agreement dated March 18, 2025. The company has secured solar panels, inverters, racking, and transformers through partnerships with Tier 1 suppliers, ensuring the project stays on track.

Commenting on the deal, Dr. Richard Lu, CEO of SolarBank, explained that this was the eighth community solar project that will be constructed and operated for Solar Advocate as part of a relationship that originated in 2018. “The fact that they are a repeat customer is a testament to SolarBank’s ability to deliver projects and create long term sustainable value for its partners,” Dr. Lu added. “We continue to execute on our strategy of growth in the EPC segment of the business and the Independent Power Producer segment of the business.”

The company also announced that the New York State Energy Research and Development Authority (“NYSERDA”) has approved a $1,058,616 USD incentive for the project under the NY-Sun Program, which supports the expansion of solar energy in the state (https://ibn.fm/6qct4).

The incentive is contingent on the project’s completion within 30 months of approval. However, it does not increase the financial terms of the transaction with Solar Advocate. SolarBank has secured the necessary interconnection agreements with the local utility and obtained the required permits from regulatory authorities.

“SolarBank has a long-standing successful track record in working with government agencies in the United States and Canada to obtain government support and incentives for its clean and renewable energy projects,” Dr. Lu added. “While the Camillus Project has been sold to Solar Advocate, the receipt of these incentives further demonstrates SolarBank’s ability to execute and provide sustainable projects with robust financial returns.”

As construction moves forward, SolarBank continues to expand its presence in the EPC and independent power production markets, reinforcing its position in the growing community solar sector. With a development pipeline exceeding one gigawatt, the company aims to accelerate its growth in the renewable energy sector by continuously bringing new solar projects online.

The company recently announced a partnership with Viridi, an industry leader in fail-safe battery energy storage systems, to develop a combined 3.06 megawatt (“MW”) direct current ground-mounted solar power project and a 1.2 megawatt-hour (“MWh”) BESS in Buffalo, New York. Additionally, SolarBank is building three large-scale battery energy storage systems – two in Ontario and one in New York. As demand for renewable energy grows, SolarBank’s expansion into community solar projects positions the company as a key player in the transition to clean energy.

For more information, visit the company’s website at SolarBankCorp.com.

This report contains forward looking information. Please refer to the press releases entitled “$7.3 million USD Transaction Entered into with Solar Advocate Development LLC for the Sale and Construction of the Camillus Solar Project” and “SolarBank Partners with Viridi on Combined 3.06 MW Solar and 1.2 MWH Battery Energy Storage Project Located in Buffalo, New York” for additional details on the statements and related assumptions and risks.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN